Irritable Bowel Syndrome

A FODMAP-lowering diet administered through smartphone application was superior to standard medical therapy alone in improved symptom severity among patients with irritable bowel syndrome, according to a presentation at Digestive Disease Week.

Patients with Rome IV irritable bowel syndrome had more severe symptoms with negative implications on quality of life compared with patients with Rome III IBS, according to research published in Clinical Gastroenterology and Hepatology.

Salix Pharmaceuticals recently released survey results in a report, Patient Perspectives: Living with IBS in a Pandemic, offering perspectives from adults with irritable bowel syndrome during the COVID-19 pandemic.

The connection between disordered eating and GI seems like an easy one to make.

Irritable bowel syndrome is one of the most burdensome and chronic ailments with an estimated 45 million people affected in the United States, the International Foundation for Gastrointestinal Disorders reports.

In this episode, Brian E. Lacy, MD, PhD, joins us to discuss the American College of Gastroenterology’s newest guidelines for irritable bowel syndrome, options for patients with IBS-D and IBS-C, and much more.

Researchers found that specific foods and nutrients correlated with species known to have mucosal protection and anti-inflammatory effects, according to data published in Gut.

Patients with constipation-predominant irritable bowel syndrome treated with a delayed-release version of linaclotide experienced improvements in abdominal pain, according to study results.

A short-term strict low FODMAP diet and long-term ‘modified’ low FODMAP diet was linked to improvements in symptoms and quality of life in irritable bowel syndrome-diarrhea predominant patients, according to study results.

The American College of Gastroenterology released new guidelines for the treatment of patients with irritable bowel syndrome. It was the top story in gastroenterology last week.